The Triple Threat of Influenza, RSV, and Covid
CE Information
1.0 CE credit (0.5 pharmacology)Completion Time
1 hourAvailable Until
December 14, 2024
Navigate
Overview
The Triple Threat of Influenza, RSV, and Covid
Learning Objectives
Describe the clinical manifestations for influenza, RSV and COVID-19.
Evaluate diagnostic testing for influenza, RSV and COVID-19
Identify the latest evidence-based treatment guidelines for influenza, RSV and COVID-19.
Discuss oral antivirals Paxlovid, molnupiravir (Lagevrio), and intravenous antiviral remdesivir (Veklury®) used as pharmacotherapies for COVID-19.
Discuss the four FDA-approved antiviral drugs recommended to treat flu: oseltamivir phosphate (Tamiflu®), zanamivir (Relenza®), peramivir (Rapivab®), and baloxavir marboxil (Xofluza®) for influenza.
Discuss antipyretics and pain relievers used as pharmacotherapies for RSV and harm in using aspirin in children.
Describe vaccine availability for COVID-19, influenza, and RSV.
CE Information
This activity offers 1.0 CE credit (0.5 pharmacology) to attendees.
Accredited by American Association of Nurse Practioners.
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.5 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 23116443. This activity was planned in accordance with AANP Accreditation Standards and Policies.